2. Academic Validation
  3. Hyperbranched polyamidoamine-RGD peptide/si- circICA1 in the treatment of invasive thyroid cancer through targeting of the miR-486-3p/SERPINA1 axis

Hyperbranched polyamidoamine-RGD peptide/si- circICA1 in the treatment of invasive thyroid cancer through targeting of the miR-486-3p/SERPINA1 axis

  • Nanomedicine (Lond). 2023 Dec 22. doi: 10.2217/nnm-2023-0211.
Shuai Dong 1,  Qing Xia 2,  Jun Pan 1,  Xiao-Long Du 1,  Yi-Jun Wu 1,  Xiao-Jun Xie 1
Affiliations

Affiliations

  • 1 Department of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • 2 Department of Endocrinology, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, China.
PMID: 38131284 DOI: 10.2217/nnm-2023-0211
Abstract

Aim: This study aimed to identify molecular markers associated with papillary thyroid Cancer (PTC) and investigate the therapeutic potential of targeted nanoscale drugs. Materials & methods: We analyzed the effects of circICA1 and miR-486-3p on B-CPAP cells' proliferation, Apoptosis, migration and invasion. The regulation of the miR-486-3p/SERPINA1 axis was explored using quantitative real-time Reverse transcription PCR and western blot analyses for metastasis. In vivo, we evaluated the effects of hyperbranched polyamidoamine-RGD peptide/si-circICA1 on PTC growth and metastasis. Results: Enhanced miR-486-3p expression inhibits B-CPAP cells' proliferation and invasion. si-circICA1 delivered via hyperbranched polyamidoamine-RGD peptide nanoparticles shows potential for treating metastasis in PTC. Conclusion: This study identifies key molecular mechanisms underlying PTC invasiveness and suggests a promising therapeutic strategy for PTC using targeted nanoscale drugs.

Keywords

HPAA-RGD; SERPINA1; circICA1; miR-486-3p; papillary thyroid cancer.

Figures
Products